News and Analysis | Published:

Tissue-agnostic cancer drug pipeline grows, despite doubts

Nature Reviews Drug Discovery volume 17, pages 227229 (2018) | Download Citation

The FDA could soon approve the first drug developed explicitly for a tissue-agnostic cancer indication, but biological complexity may limit this approach.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nrd.2018.6

Authors

  1. Search for Ken Garber in:

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing